{"organizations": [], "uuid": "0a0d583dfeabd6dca6c5cde3d333cab807a1ac88", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-united-therapeutics-says-fda-accep/brief-united-therapeutics-says-fda-accepted-to-review-its-nda-for-implantable-system-for-remodulin-idUSFWN1RC020", "country": "US", "domain_rank": 408, "title": "BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-30T23:48:00.000+03:00", "replies_count": 0, "uuid": "0a0d583dfeabd6dca6c5cde3d333cab807a1ac88"}, "author": "", "url": "https://www.reuters.com/article/brief-united-therapeutics-says-fda-accep/brief-united-therapeutics-says-fda-accepted-to-review-its-nda-for-implantable-system-for-remodulin-idUSFWN1RC020", "ord_in_thread": 0, "title": "BRIEF-United Therapeutics Says FDA Accepted To Review Its NDA For Implantable System For Remodulin", "locations": [], "entities": {"persons": [{"name": "remodulin", "sentiment": "none"}], "locations": [], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "nda for implantable system for remodulin reuters staff", "sentiment": "none"}, {"name": "sec", "sentiment": "none"}, {"name": "united therapeutics", "sentiment": "none"}, {"name": "min read    united therapeutics corp", "sentiment": "none"}, {"name": "fda co's nda", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 30 (Reuters) - United Therapeutics Corp:\n* UNITED THERAPEUTICS- NOTIFIED BY FDA CO'S NDA FOR IMPLANTABLE SYSTEM FOR REMODULIN ACCEPTED FOR 6-MONTH REVIEW AS CLASS 2 RESUBMISSION - SEC FILING Source text: ( bit.ly/2E6Hb6r ) Further company coverage:\n ", "external_links": [], "published": "2018-03-30T23:48:00.000+03:00", "crawled": "2018-03-31T00:03:37.016+03:00", "highlightTitle": ""}